Recursion Pharmaceuticals, Inc. (RXRX) Profit Margins
Over the twelve months to 2026-06-30, Recursion Pharmaceuticals, Inc. (RXRX) had gross margin 3.5%, operating margin -991.7%, net margin -945.9%, free cash flow margin -642.2%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RXRXRecursion Pharmaceuticals, Inc.Follow RXRX — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Gross margin | — | -21.2% | 4.5% | 23.1% | 5.0% | 3.5% | |
| Operating margin | -1795.8% | -616.7% | -785.3% | -814.1% | -867.9% | -991.7% | |
| Net margin | -1832.2% | -601.0% | -736.0% | -788.0% | -863.4% | -945.9% | |
| FCF margin | -1949.4% | -302.6% | -672.4% | -633.7% | -506.5% | -642.2% |
USD billions · SEC XBRL
Recursion Pharmaceuticals, Inc. — questions
- What is Recursion Pharmaceuticals, Inc.'s gross margin?
- 3.5% over the twelve months to 2026-06-30.
- What is Recursion Pharmaceuticals, Inc.'s operating margin?
- -991.7% over the twelve months to 2026-06-30.
- What is Recursion Pharmaceuticals, Inc.'s net profit margin?
- -945.9% over the twelve months to 2026-06-30.
Every figure on this page comes from Recursion Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.